bpc 157 human clinical trials 2025 Frontiers FDA's Review Of Peptides Signals

In the companys supplemental NDA, Neurocrine included data from the Phase III KINECT-HD trial and the ongoing KINECT-HD2 open-label study to establish the safety and efficacy of Ingrezza in the proposed indication

But if study endpoints measure lasting structural brain changes, synaptic density, neuroprotection, or recovery from injury, the biological evidence supports intermittent administration

An FDA-approved drug comes with a defined indication, a validated dosing protocol, a safety surveillance system, and manufacturer accountability

Now what

AOD-9604 A peptide fragment studied for fat metabolism and lipolysis without the blood sugar or growth hormone side effects associated with full GH therapy